|RxNews Recap for 03-25-11|
|By BioMedReports.com Staff|
|Friday, 25 March 2011 18:46|
Biostar Pharmaceuticals (NASDAQ:BSPM) said Friday its fourth quarter profit more than tripled due to strong sales of its flagship hepatitis B drug, prompting a huge spike in the company's share price.
Callidus Software Inc. (NASDAQ: CALD), the leader in Sales Performance Management (SPM), announced today that it is a sponsor at the 9th Annual Sales Force Effectiveness Europe 2011 Conference, organized by eyeforpharma.
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced today that Standard & Poor's (S&P) will add Edwards to the S&P 500 Index after the close of trading on Thursday, March 31, 2011.
First China Pharmaceutical Group, Inc. (OTCBB:FCPG) is pleased to announce that a US $3,000,000 capital financing is well under way with US$2.7 million recently closed.
Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) today announced that it has completed patient enrollment in its U.S. Phase 2 clinical trial (REO 015) using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers.